子宫内膜癌中EZH2过表达:NRG Oncology/GOG研究
本研究基于GOG 210方案,采用RT-PCR和Western blot检测60例子宫内膜样腺癌肿瘤及27例匹配正常苗勒管组织中EZH2的表达。肿瘤组织EZH2 mRNA和蛋白表达均显著高于匹配正常组织(均p<.0001)。EZH2表达与生存无统计学显著差异,但高表达者无进展生存有下降趋势。
要点
- 肿瘤组织EZH2 mRNA和蛋白表达均显著高于匹配正常组织(均p<.0001)。
- EZH2蛋白表达与淋巴血管间隙浸润相关(p=.044),mRNA表达与年龄相关(p=.037)。
- EZH2表达与生存无统计学显著差异,但高表达者无进展生存有下降趋势。
核心结论
- 结果证实EZH2在子宫肿瘤中较正常组织存在差异表达。
- 子宫内膜癌患者中EZH2表达与生存无统计学显著差异。
研究设计与样本
- 基于GOG 210方案入组参与者,采用实时逆转录聚合酶链反应(RT-PCR)和Western blot(WB)分析早期和晚期子宫内膜样腺癌组织及部分匹配正常苗勒管组织的EZH2表达。
- 采用非参数方法评估mRNA和蛋白表达与已知临床/病理预后因素的差异,采用Cox比例风险模型等生存分析技术评估基于EZH2表达的无进展生存(PFS)和总生存(OS)差异。
主要发现
- 肿瘤标本EZH2 mRNA表达显著高于匹配正常组织(p<.0001)。
- 肿瘤标本EZH2蛋白表达显著高于匹配正常组织(p<.0001)。
- 原发肿瘤中EZH2蛋白表达与淋巴血管间隙浸润(LVSI)相关(p=.044)。
- 原发肿瘤中EZH2 mRNA表达与年龄相关(p=.037)。
- 原发肿瘤与匹配正常组织间EZH2表达差异与其他已知临床和病理因素无关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Enhancer of zeste homolog 2 (EZH2) is a histone methyl transferase that mediates epigenetic silencing of tumor suppressor genes. It is commonly over-expressed in several solid tumors and has been shown to be a prognostic biomarker. We investigated patterns of EZH2 expression in endometrial cancer. METHODS: Evaluation of EZH2 expression was completed on both early and advanced stage endometrioid adenocarcinoma tissues and a subset of matched normal mullerian tissue samples, from participants enrolled in Gynecologic Oncology Group (GOG) protocol 210, using real time reverse transcription polymerase chain reaction (RT-PCR) and western blot (WB) analysis. Non-parametric methods were used to assess differences in mRNA and protein expression respectively with known clinical/pathologic prognostic factors. Survival analysis was performed using techniques including Cox proportional hazards (PH) model to evaluate differences in progression free survival (PFS) and overall survival (OS) based on EZH2 expression. RESULTS: Eighty-seven patient samples were analyzed that included 60 tumors and 27 matched-normal tissue specimens. EZH2 mRNA (p < .0001) and protein expression (p < .0001) in tumor specimens were significantly higher than in matched-normal tissue. In primary tumors, EZH2 protein expression was associated with lympho-vascular space invasion (LVSI, p = .044), and EZH2 mRNA expression was associated with age (p = .037). Differences in EZH2 expression between primary tumors and matched normal tissue were not associated with other known clinical and pathologic factors. However, there did appear to be a trend toward decreased progression-free survival among patients with high EZH2 expression levels. CONCLUSIONS: Our results confirm the differential expression of EZH2 in uterine cancers compared to normal tissues. However, there were no statistically significant differences in survival associated with EZH2 expression in patients with endometrial cancer. NCT #: NCT00340808.
引用
- Krill L, Deng W, Eskander R, et al. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2019. PMID: 31843273. doi:10.1016/j.ygyno.2019.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。